We report a case of a 13-year-old girl with soft tissue sarcoma of the hand, which showed muscle and neuroectodermal immunophenotypes. Molecular studies were performed on RNA collected from fine-needle aspiration (FNA) cytology and peripheral blood samples by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis. This biphenotypic tumor showed simultaneous expression of EWS-FLI1 and PAX3-FKHR transcripts, specific of Ewing family tumors and alveolar rhabdomyosarcoma, respectively. Although childhood sarcomas with simultaneous muscle and neural differentiation have been described to have EWS-FLI1 transcripts, there are no reports of tumors with both transcripts. Cytological specimens are a good source of RNA for molecular studies.
INTRODUCTION
Small round cell tumors of childhood remain a diagnostic challenge to the surgical pathologist because they share several morphological features and are often difficult to distinguish from each other. Because effective therapeutic protocols are available, an accurate diagnosis is needed to institute appropriate therapy and predict prognosis. Consistent cytogenetic alterations have been identified in several members of this family, including alveolar rhabdomyosarcoma, Ewing's sarcoma/peripheral neuroectodermal tumor (PNET), and desmoplastic small round cell tumor. 1 Recently, these chromosomal translocations have been characterized at the molecular level and found to result in PAX3-FKHR or PAX7-FKHR chimeric genes in alveolar rhabdomyosarcoma, 2 EWS-FLI1 and EWS-ERG gene fusions in Ewing's sarcoma/ PNET, 3 and EWS-WT1 gene fusions in desmoplastic small round cell tumor (DSRCT) 4 Chimeric transcripts and gene fusions specific for each translocation can be detected in clinical samples by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescent in situ hybridization (FISH), and are proving to be a reliable and very useful diagnostic technique in the small round cell tumor family. 1, 5 In this case study, we apply these molecular assays to detect chimeric transcripts in cytological specimens and peripheral blood samples in a sarcoma with neuroectodermal and muscle differentiation.
CASE REPORT
A 13-year-old girl developed a painful soft tissue mass in the hypothenar region of the left hand. A magnetic resonance imaging (MRI) scan showed a poorly circumscribed mass, 2 cm in diameter, without bone involvement. An open biopsy was performed. It disclosed ( Fig 1A) an undifferentiated solid tumor made up of strands of small cells with hyperchromatic nuclei and scant cytoplasm, with material that tested positively with periodic acid-Schiff (PAS). The patient was referred to our hospital under the diagnosis of extraskeletal Ewing's sarcoma.
Once admitted in our hospital, a left axillary mass was detected. FNAs were performed in both the axilla and the left hand mass. They showed the same cytological picture, including small cells with hyperchromatic nuclei, sometimes eccentric, finely stippled chromatin, occasional nucleoli, and a scant eosinophilic cytoplasm with a small number of multinucleated cells were seen. An immunohistochemical study was performed on the FNA smears of both locations with antibodies for pan-cytokeratins, vimentin, desmin, S-100 protein, NSE, and O13. Cytoplasmic immunoreactivity was detected for vimentin, S-100 protein, NSE, O13 (Fig 1B) , and desmin ( Fig 1C) .
A treatment program following the protocol for highgrade sarcoma, including radiotherapy and high-dose chemotherapy, was administered. Two months later, the axillary mass was resected. It corresponded to a lymph node in which necrotic tumor nests were seen in a fibrotic background. A small number of viable tumor cells was seen with features similar to those in previous samples ( Fig 1D) . The patient was discharged in good status and is currently finishing the treatment protocol with no gross evidence of disease.
MOLECULAR STUDIES
Available samples for molecular studies include in chronological order: FNAs of the left hand mass and lymph node, lymph node excision, and four peripheral blood samples (PBS). The first was taken 2 weeks after the FNAs, and the remaining samples on a monthly basis.
RNA extraction was performed immediately after the samples were taken with a modified guanidine isothiocyanate method, using the reagent TRIZOL (Gibco BRL). Search for chimeric transcripta was then performed by nested RT-PCR using 1 µg of total RNA as template and a GeneAmp RNA-PCR kit (Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ) using the manufacturer's recommendations. Reverse transcription included an incubation period of 45 minutes at 42°C with random hexamers, followed by a 5-minute period at 99°C to denature the enzyme. PCR was then performed with an initial denaturation step of 95°C for 2 minutes, followed by 35 cycles including a denaturation step at 94°C for 30 seconds, annealing at 66°C (68°C for the second round) for 30 seconds, and extension at 72°C for 60 seconds, with 7 minutes of extension after the completion of the last cycle. A second round of amplification was performed in PBS. One fifth of the initial PCR product was amplified with a second set of specific internal primers. All PCR products were identified by 2% agarose gel electrophoresis and ethidium bromide staining, and then blotted into nylon membranes (Hybond+; Nycomed Amersham, Buckinghamshire, United Kingdom), and detected with internal probes labeled with chemoluminiscence (Nycomed Amersham). Specific primers and probes were used to amplify EWS-FLI1, EWS-ERG, PAX3-FKHR, and EWS-WT1 and have been reported elsewhere. 5, 6 EWS-FLI1 chimeric transcripts were detected in FNA but not in PBS. The length of the amplified product was constant (Fig 2) . Sequencing of the RT-PCR product revealed an in-frame fusion of EWS exon 7 to FLIl exon 6, 329 base pairs in length. PAX3-FKHR chimeric transcripts (Fig 3) were present in the FNAs performed on the hand mass and on the axillary lymph node. They were not present, however, in the lymph node excision, 2 months later. EWS-ERG and EWS-WT1 transcripts were not found in any sample.
DISCUSSION
Malignant ectomesenchymomas are sarcomas where areas of neural and muscle differentiation are seen. Its primitive variants are composed of undifferentiated cells, resembling peripheral neuroepithelioma in some areas and alveolar rhabdomyosarcoma in others. 7 Our results show a soft tissue tumor in which a double differentiation occurred. Immunohistochemical studies support both neuroectodermal and muscle differentiation. Moreover, simultaneous expression of EWS-FLI1 and PAX3-FKHR fusion transcripts could be shown in this tumor. Those gene fusions are considered specific for Ewing family tumors and alveolar rhabdomyosarcomas, respectively. Reports in which simultaneous investigation of several chimeric transcripts have been performed in small round cell tumors have shown a high correlation between histopathological entities and chimeric transcripts. 4, 5 EWS-FLI1 chimeric transcripts have been found in undifferentiated tumors that have morphology that is not consistent with ES/PNET, such as the cases reported by Thorner et al 8 or an intraabdominal small round cell tumor with morphological features of a DSRCT. 9 None of these studies, however, report the simultaneous finding of two chimeric transcripts in a given tumor. EWS-FLI1 transcripts were also reported in a series of childhood malignant ectomesenchymomas. 10 The authors described six biphenotypic sarcomas with both neural and muscle differentiation appearing in soft tissues of the chest, the extremities, or retroperitoneum in patients between the ages of 5 months and 25 years. Interestingly, all these tumors expressed EWS-FLI1 transcripts identical to those of the Ewing family of tumors. None of the cases expressed any other transcript, including PAX3-FKHR. In another study, however, one of two ectomesenchymomas studied showed the PAX3-FKHR fusion gene, which is associated with alveolar rhabdomyosarcomas, without evidente of EWS-FLI1 transcripts.
11 A primitive ectomesenchymoma cell fine has been reported to have the t(11;22) (q24;q12) associated with the Ewing family of tumors and another rearrangement involving the band 13q14, one of the breakpoints of the t(2;13) (q35; q14) translocation of alveolar rhabdomyosarcoma, which was not present. 12 Our case is unique for being a primitive malignant ectomesenchymoma expressing both transcripts.
FNA has been used in small round cell childhood tumors to obtain material suitable to perform cytogenetic studies, 13 but karyotypes are laborious and often unsuccessful. As far as we know, this is the second report in which EWS-FLI1 transcripts have been found on cytological specimens, 13 and the first in which PAX3-FKHR fusions are detected in FNA material. Our study indicates that material obtained from FNAs, if immediately processed, is probably an excellent source of RNA for molecular studies. RT-PCR is sensitive enough to detect chimeric transcripts in small samples of aspirated tissue.
The high sensitivity of RT-PCR permits the detection of fusion RNAs in peripheral blood samples, a promising assay to detect circulating tumor cells and minimal residual disease in undifferentiated sarcomas of childhood. It is being used in patients with Ewing family tumors 6 and alveolar rhabdomyosarcomas 14 as a possible means to monitor therapy. In our case, it allowed us to monitor the presence of EWS-FLI1 transcripts in the patient while she was undergoing treatment in which all PBS are negative for transcripts. However, the possible prognostic value of chimeric RNA detection in childhood sarcomas is still unclear.
The expression of two transcripts seems to be an exceptional feature in childhood tumors. Two possible explanations include primitive cells capable of differentiating simultaneously along two different pathways, or one of these two transcripts could be a secondary genetic alteration on an otherwise conventional alveolar rhabdomyosarcoma or Ewing family tumor. Tumors with divergent differentiation such as desmoplastic small round cell tumor are a good example of the first possibility, and a challenge to tumor classification. 5 Because secondary molecular features in pediatric tumors have to be further described, the second possibility cannot be discarded. Regardless of etiology, this case has shown that neither morphology or our current molecular knowledge are sufficient to classify rare cases of childhood solid tumors. 
